Latest IOVA news

Iovance Maps TIL Therapy Expansion After Record Revenue and Margin Gains

MarketBeat · Sat, 19 Sep 2026 07:02:48 -0400

Iovance Biotherapeutics NASDAQ: IOVA said it is expanding its tumor-infiltrating lymphocyte, or TIL, therapy platform across multiple solid-tumor indications after reporting a record second quarter marked by nearly $100 million in revenue and a 56% margin.

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewsWire · Fri, 18 Sep 2026 17:10:00 -0400

SAN CARLOS, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on September 17, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 179,750 shares of Iovance's common stock to eighteen new, non-executive employees.

4 Biotech Stocks to Watch as Potential Takeover Targets

Zacks Investment Research · Fri, 18 Sep 2026 13:35:54 -0400

Biotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers seek late-stage and commercial assets.

Iovance Biotherapeutics to Present at Upcoming Conferences

GlobeNewsWire · Fri, 04 Sep 2026 08:00:00 -0400

SAN CARLOS, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following upcoming conferences:

Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves

Zacks Investment Research · Thu, 27 Aug 2026 11:51:05 -0400

Oncology innovation is driving new treatment options, with Iovance, Merit Medical and Kura advancing cancer-focused therapies and technologies.

Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen

Zacks Investment Research · Thu, 27 Aug 2026 05:31:07 -0400

Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.

5 Biotech Stocks Worth Adding to Your Portfolio Now

Zacks Investment Research · Wed, 26 Aug 2026 11:20:19 -0400

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector.

Market information is provided for research and visualization and is not investment advice.